Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

July 28, 2025 - DALLAS People in 15 regions across the U.S. will soon benefit from the American Heart Association's ...

Queen’s University Belfast spin-out company Re-Vana Therapeutics has signed a landmark collaboration deal with German ...

Boehringer Ingelheim and Re-Vana Therapeutics, a USA and UK based developer of ocular therapeutics and ocular drug delivery ...

Re-Vana Therapeutics partners Boehringer Ingelheim to develop long-acting eye treatments positioning Northern Ireland as a ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...